Trexquant Investment LP Has $346,000 Stake in Bausch + Lomb Co. (NYSE:BLCO)

Trexquant Investment LP cut its stake in Bausch + Lomb Co. (NYSE:BLCO - Free Report) by 70.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,147 shares of the company's stock after selling 46,127 shares during the period. Trexquant Investment LP's holdings in Bausch + Lomb were worth $346,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of BLCO. Blue Trust Inc. increased its position in Bausch + Lomb by 68.3% in the fourth quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock worth $48,000 after purchasing an additional 1,004 shares during the period. FNY Investment Advisers LLC bought a new position in shares of Bausch + Lomb in the 4th quarter valued at about $72,000. Commonwealth Equity Services LLC acquired a new stake in shares of Bausch + Lomb during the 4th quarter worth approximately $181,000. Orion Portfolio Solutions LLC bought a new stake in shares of Bausch + Lomb during the fourth quarter worth approximately $225,000. Finally, Verition Fund Management LLC acquired a new position in Bausch + Lomb in the third quarter valued at approximately $302,000. 11.07% of the stock is currently owned by institutional investors and hedge funds.

Bausch + Lomb Stock Up 1.8 %

Shares of BLCO stock traded up $0.22 during trading hours on Friday, hitting $12.07. 845,194 shares of the company were exchanged, compared to its average volume of 617,362. The company has a market capitalization of $4.26 billion, a PE ratio of -13.26, a PEG ratio of 0.85 and a beta of 0.54. Bausch + Lomb Co. has a 52 week low of $10.46 and a 52 week high of $21.69. The business has a 50 day moving average of $14.61 and a two-hundred day moving average of $17.37. The company has a current ratio of 1.60, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The company reported $0.25 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.02. Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The company had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.26 billion. During the same period in the previous year, the company posted $0.24 earnings per share. The company's quarterly revenue was up 9.1% compared to the same quarter last year. Analysts anticipate that Bausch + Lomb Co. will post 0.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BLCO has been the subject of several recent research reports. Wells Fargo & Company reiterated an "equal weight" rating and set a $15.00 target price (down previously from $24.00) on shares of Bausch + Lomb in a research report on Friday, March 28th. Bank of America cut their target price on Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating on the stock in a research note on Thursday, February 20th. HC Wainwright restated a "buy" rating and set a $23.00 target price on shares of Bausch + Lomb in a report on Tuesday, February 18th. Needham & Company LLC reaffirmed a "hold" rating on shares of Bausch + Lomb in a research note on Thursday, February 20th. Finally, Stifel Nicolaus reduced their price objective on shares of Bausch + Lomb from $17.00 to $15.00 and set a "hold" rating on the stock in a research note on Thursday, April 3rd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, Bausch + Lomb has an average rating of "Hold" and an average target price of $18.82.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.